Value
8.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 9.2 |
| EV/EBITDA | 10.0 |
| Fwd P/E | 5.0 |
| PEG | 9.5 |
| Analyst target | 9.0 |
- ▸Forward P/E: 25.0x
- ▸PEG: 0.58
- ▸Attractively valued
CRMD · Why this verdict
Why CorMedix (CRMD) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score7.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
CorMedix shows elite quality metrics — a 66% ROE, 45% margins, a Rule of 40 score of 256, and a 9/9 Piotroski F-Score — consistent with a genuine compounder rather than a speculative biotech. Quality breakdown | ROE stays above 50% and the Piotroski F-Score remains at 8 or 9 over the next fiscal year, confirming sustained high-quality fundamentals. | →Stable |
| CounterThe same quality notes flag an earnings-quality warning of 66% FCF/NI conversion, below full conversion, suggesting some reported profitability isn't yet converting cleanly to cash. | ||
CorMedix has beaten earnings estimates in 3 of the last 4 quarters and carries a PEG ratio of 0.58, pointing to an attractively priced grower with a track record of execution. Bull case | The company beats consensus EPS estimates again at the next print, extending the beat streak to 4 of 5. | →Stable |
| CounterConsensus embeds an approximately 84% earnings decline off a cyclical peak, so even a 'beat' could be against a much lower bar and not indicate real acceleration. | ||
A hard death-cross gate failure and a -7.0%/30-day 200-day moving-average slope confirm the stock is in a technically confirmed downtrend despite strong fundamentals. Warnings | Momentum score recovers above the 5.5 threshold and the death-cross gate clears within two quarters. | →Stable |
| CounterStrong quality and earnings metrics could be masking a market view that momentum won't recover soon, since momentum sits at only 4.9, below the 5.5 bar. | ||
A 19% short interest combined with a 7.5 quality score sets up a potential short-squeeze dynamic, and a put/call ratio of 1.75 with 82% implied volatility signals elevated options-market hedging. Risk breakdown | Short interest declines below 10% of float or the stock experiences a squeeze-driven rally of at least 20% within two quarters. | →Stable |
| CounterElevated short interest could instead reflect informed bearish positioning ahead of confirmed technical deterioration, not an unwarranted squeeze setup. | ||
The position-sizing engine assigns strong conviction and a 20% quality premium to CorMedix, reflecting close alignment between data quality and bullish signals. Position-sizing math | Conviction remains elevated or upgrades further as data quality and signal alignment persist over the next two quarters. | →Stable |
| CounterHigh ATR-driven volatility (4.6%) underlying the position-sizing factors means price swings could just as easily reverse conviction if momentum fails to recover. | ||
CorMedix shows elite quality metrics — a 66% ROE, 45% margins, a Rule of 40 score of 256, and a 9/9 Piotroski F-Score — consistent with a genuine compounder rather than a speculative biotech.
→StableQuality breakdown
- Expectation
- ROE stays above 50% and the Piotroski F-Score remains at 8 or 9 over the next fiscal year, confirming sustained high-quality fundamentals.
CounterThe same quality notes flag an earnings-quality warning of 66% FCF/NI conversion, below full conversion, suggesting some reported profitability isn't yet converting cleanly to cash.
CorMedix has beaten earnings estimates in 3 of the last 4 quarters and carries a PEG ratio of 0.58, pointing to an attractively priced grower with a track record of execution.
→StableBull case
- Expectation
- The company beats consensus EPS estimates again at the next print, extending the beat streak to 4 of 5.
CounterConsensus embeds an approximately 84% earnings decline off a cyclical peak, so even a 'beat' could be against a much lower bar and not indicate real acceleration.
A hard death-cross gate failure and a -7.0%/30-day 200-day moving-average slope confirm the stock is in a technically confirmed downtrend despite strong fundamentals.
→StableWarnings
- Expectation
- Momentum score recovers above the 5.5 threshold and the death-cross gate clears within two quarters.
CounterStrong quality and earnings metrics could be masking a market view that momentum won't recover soon, since momentum sits at only 4.9, below the 5.5 bar.
A 19% short interest combined with a 7.5 quality score sets up a potential short-squeeze dynamic, and a put/call ratio of 1.75 with 82% implied volatility signals elevated options-market hedging.
→StableRisk breakdown
- Expectation
- Short interest declines below 10% of float or the stock experiences a squeeze-driven rally of at least 20% within two quarters.
CounterElevated short interest could instead reflect informed bearish positioning ahead of confirmed technical deterioration, not an unwarranted squeeze setup.
The position-sizing engine assigns strong conviction and a 20% quality premium to CorMedix, reflecting close alignment between data quality and bullish signals.
→StablePosition-sizing math
- Expectation
- Conviction remains elevated or upgrades further as data quality and signal alignment persist over the next two quarters.
CounterHigh ATR-driven volatility (4.6%) underlying the position-sizing factors means price swings could just as easily reverse conviction if momentum fails to recover.
TrendMatrix Research · core thesis
Engine thesis — one sentence
CorMedix combines elite-quality fundamentals and a 3-of-4 earnings beat streak with a technically confirmed downtrend and short-squeeze setup, making it a quality-value name awaiting a momentum inflection.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
9.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.9 |
| FCF quality | 5.1 |
| Moat | 8.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 66%
- ▸Strong margins: 45%
- ▸Earnings quality warning: 66% FCF/NI
- ▸Wide economic moat
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.2 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.0%/30d — confirmed downtrend
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.0 |
| Analyst rating | 6.5 |
| Price target | 9.9 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 74%
Insider
5.0/10data confidence 50%Peer rank
7.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.2 |
| quality rank | 9.1 |
| growth rank | 9.6 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.1 |
| support resistance | 2.1 |
| 52w position | 0.0 |
Risk (lower is worse)
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.1 |
| days to cover | 0.0 |
| volatility | 1.1 |
| put call | 1.7 |
| implied vol | 0.0 |
| beta | 5.1 |
| debt equity | 8.7 |
- ▸Short squeeze setup: 19% short, quality 7.5
- ▸Elevated put/call: 1.75
- ▸High IV: 85%
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality-value play. Wait for momentum improvement.
Engine technical detail
verdict_path:
L4:PATH_C_QUALITY_VALUE_WAITPassed (8)
- MOMENTUM:4.9>=4.5
- ASYMMETRY:3.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
3.58
Upside
+51.1%
Downside
14.3%
Sizing output
STARTER
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Drawdown -50% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The C-path quality+value combination triggered the STRONG_BUY_WAIT verdict: quality 9.3 and value 8.6 both clear their thresholds, with asymmetric R:R of 3.58 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 9.3, and Value at 8.6; the weakest are Technical at 1.7, Risk (lower is worse) at 3.5, and Momentum at 4.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 3.58 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Quality Compounder Metrics
Trip ifROE falls below 30% or the Piotroski F-Score drops below 6 in the next annual report, indicating quality deterioration.
- P2Earnings Beat Streak Value
Trip ifCorMedix misses consensus EPS estimates by more than 10% at its next earnings report.
- P3Death Cross Momentum Risk
Trip ifThe stock closes below the 200-day moving average for more than 90 consecutive days without the death-cross gate clearing.
- P4Short Squeeze Setup Risk
Trip ifShort interest rises above 25% of float while the stock price falls more than 15% from current levels.
- P5Position Sizing Conviction Signal
Trip ifConviction rating drops to the lowest tier at the next data refresh, or ATR volatility exceeds 6%.